Stephen Liu
MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Apr 30, 2024
Episode
215
Soundcloud
Share
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, focusing on non-G12C mutations. KRAS mutations are very common in lung cancer and while there are now multiple approved and active KRAS inhibitors, they are specifically for the G12C mutation. Newer strategies are needed for other common mutations, such as KRAS G12V and G12D, and fortunately, new drugs are on the horizon.
Guest
Mariana Brandao
MD
Medical Oncologist
Institut Jules Bordet
University of Brussels
Rajwanth R. Veluswamy
MD
Associate Professor of Medicine, Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
